| خلاصه مقاله | Prostate Cancer (PCa) is introduced as the second most prevalent cancer in the men group. In recent decades, PCa has emerged as a prominent life-threatening condition among older men. Radiation and surgical therapies treat this disease when it first appears in a localized form. Androgen deprivation therapy, hormonal therapy, chemotherapy, and other forms of treatment are frequently utilized as therapeutic strategies. However, many investigations have revealed numerous side effects after using these treatments. In the present study, various immunoinformatic approaches are being used to create a multi-epitope peptide vaccine using the overexpressed antigenic proteins of PCa (including PSMA, PSA, STEAP, PSCA, and PAP). The multi-epitope vaccine was produced utilizing various immunological filters and rigorous immunoinformatic analysis. Although the produced epitopes offer several advantages, they have low immunogenicity, a common issue with epitope vaccines. TLR5 agonist (flagellin) may resolve this problem as a suitable adjuvant. Three peptide linkers, AYY, GPGPG, and KK, attached the anticipated CTL, HTL, and LBC epitopes, respectively. Then, we assessed the developed vaccine's physicochemical characteristics, antigenicity, allergenicity, solubility, and secondary and 3D structures. To produce a 3D structure with high quality for the designed vaccine, refinement, and validation were carried out. In addition, molecular docking revealed a significant binding with the lowest energy between the vaccine element and TLR5. Molecular simulation using normal mode analysis (NMA) showed the stability of docking complexes. A vaccine component has been done in silico cloning of the peptide for its future amplification. As a result, our multi-epitope peptide vaccine is likely to elicit cellular and humoral responses, making it a compelling candidate with appropriate physicochemical and immunological features for PCa therapy. |